Abbott D2E7 Monotherapy Use Should Afford Faster FDA Review, Abbott Says

Abbott is focusing on the need for a regular supply of an anti-TNF agent that can be dosed without methotrexate as a justification for requiring a faster review of D2E7 at FDA